Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (18,512)	$ (22,214)
Net loss attributable to noncontrolling interest		3,300	4,283
Net loss - as reported, attributable to PAVmed Inc.		(15,212)	(17,931)
Series B Convertible Preferred Stock dividends – earned		(80)	(74)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests		(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (22,788)	$ (18,005)
Weighted average common shares outstanding, basic		8,694,904	6,473,010
Weighted average common shares outstanding, diluted		8,694,904	6,473,010
Net loss attributable to PAVmed Inc. common stockholders, basic	[1]	$ (2.62)	$ (2.78)
Net loss attributable to PAVmed Inc. common stockholders, diluted	[1]	$ (2.62)	$ (2.78)

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.